Aaron Shanker1, Mohammad Bashashati2, Ali Rezaie3. 1. Department of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA. 2. Division of Gastroenterology, Department of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA. 3. GI Motility Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Ali.rezaie@cshs.org.
Abstract
PURPOSE OF REVIEW: Gastroparesis is one of the more challenging entities in the landscape of gastroenterology, posing difficulties for both patients and physicians with regard to effective management and therapies. In this article, we reviewed various gastroparesis treatment options, with an emphasis on gastric electrical stimulation (GES). RECENT FINDINGS: GES has demonstrated a significant reduction of cardinal symptoms in refractory gastroparetic patients, particularly nausea and vomiting, across multiple studies. However, GES has not been shown to conclusively decrease gastric emptying time in these patients. Such finding has led the investigators to analyze the impact of combining GES with pyloroplasty. While this treatment pathway is nascent, its results thus far reveal an amplified improvement of gastroparesis symptomatology in addition to significant reduction of gastric transit, compared to GES by itself. Limited treatment choices are available for refractory gastroparesis. Combining GES with pyloroplasty holds promise but requires further assessment in large-scale trials to fully evaluate the risks and benefits.
PURPOSE OF REVIEW: Gastroparesis is one of the more challenging entities in the landscape of gastroenterology, posing difficulties for both patients and physicians with regard to effective management and therapies. In this article, we reviewed various gastroparesis treatment options, with an emphasis on gastric electrical stimulation (GES). RECENT FINDINGS: GES has demonstrated a significant reduction of cardinal symptoms in refractory gastropareticpatients, particularly nausea and vomiting, across multiple studies. However, GES has not been shown to conclusively decrease gastric emptying time in these patients. Such finding has led the investigators to analyze the impact of combining GES with pyloroplasty. While this treatment pathway is nascent, its results thus far reveal an amplified improvement ofgastroparesis symptomatology in addition to significant reduction of gastric transit, compared to GES by itself. Limited treatment choices are available for refractory gastroparesis. Combining GES with pyloroplasty holds promise but requires further assessment in large-scale trials to fully evaluate the risks and benefits.
Authors: Richard W McCallum; William Snape; Fredrick Brody; John Wo; Henry P Parkman; Thomas Nowak Journal: Clin Gastroenterol Hepatol Date: 2010-06-09 Impact factor: 11.382
Authors: Brian R Davis; Irene Sarosiek; Mohammad Bashashati; Ben Alvarado; Richard W McCallum Journal: J Gastrointest Surg Date: 2016-11-28 Impact factor: 3.452
Authors: Michael Camilleri; Henry P Parkman; Mehnaz A Shafi; Thomas L Abell; Lauren Gerson Journal: Am J Gastroenterol Date: 2012-11-13 Impact factor: 10.864
Authors: R W McCallum; I Sarosiek; H P Parkman; W Snape; F Brody; J Wo; T Nowak Journal: Neurogastroenterol Motil Date: 2013-07-29 Impact factor: 3.598